Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Tobias E Larsson"'
Autor:
Jay L Koyner, Andre Lamy, C David Mazer, Nicolas Noiseux, Benoit de Varennes, Johannes Boehm, Matthias Thielmann, Claudio Ronco, Niloufar Siadati-Fini, Felix Wirth, Andrej Myjavec, Craig D Brown, Andreas Boening, Tobias E Larsson, Ronny Renfurm, Maxime Laflamme
Publikováno v:
BMJ Open, Vol 13, Iss 4 (2023)
Introduction Acute kidney injury (AKI) is a common complication after cardiac surgery (CS) and is associated with adverse short-term and long-term outcomes. Alpha-1-microglobulin (A1M) is a circulating glycoprotein with antioxidant, heme binding and
Externí odkaz:
https://doaj.org/article/0d3d023ac8cf44fcbf4b88db2d4a2c83
Autor:
Hannes Olauson, Karolina Lindberg, Risul Amin, Tadatoshi Sato, Ting Jia, Regina Goetz, Moosa Mohammadi, Göran Andersson, Beate Lanske, Tobias E Larsson
Publikováno v:
PLoS Genetics, Vol 9, Iss 12, p e1003975 (2013)
Klotho acts as a co-receptor for and dictates tissue specificity of circulating FGF23. FGF23 inhibits PTH secretion, and reduced Klotho abundance is considered a pathogenic factor in renal secondary hyperparathyroidism. To dissect the role of parathy
Externí odkaz:
https://doaj.org/article/c03e0589a7364e2d9a3ea05f66081ee1
Autor:
Karolina Lindberg, Hannes Olauson, Risul Amin, Arvind Ponnusamy, Regina Goetz, Rebecca F Taylor, Moosa Mohammadi, Ann Canfield, Karolina Kublickiene, Tobias E Larsson
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e60658 (2013)
Recent studies support a role for FGF23 and its co-receptor Klotho in cardiovascular pathology, yet the underlying mechanisms remain largely elusive. Herein, we analyzed the expression of Klotho in mouse arteries and generated a novel mouse model har
Externí odkaz:
https://doaj.org/article/2c3e4060d78a46f98c1066ca1813ecc6
Autor:
Helen V. Alderson, Rajkumar Chinnadurai, Sara T. Ibrahim, Ozgur Asar, James P. Ritchie, Rachel Middleton, Anders Larsson, Peter J. Diggle, Tobias E. Larsson, Philip A. Kalra
Publikováno v:
BMC Nephrology, Vol 22, Iss 1, Pp 1-7 (2021)
Abstract Background Fibroblast growth factor23 (FGF23) is elevated in CKD and has been associated with outcomes such as death, cardiovascular (CV) events and progression to Renal Replacement therapy (RRT). The majority of studies have been unable to
Externí odkaz:
https://doaj.org/article/ec22bf7e906a4671bdc03c893b33bbc7
Autor:
C David Mazer, Niloufar Siadati-Fini, Johannes Boehm, Felix Wirth, Andrej Myjavec, Craig D Brown, Jay L Koyner, Andreas Boening, Daniel T Engelman, Tobias E Larsson, Ronny Renfurm, Benoit de Varennes, Nicolas Noiseux, Matthias Thielmann, Andre Lamy, Maxime Laflamme, Thilo von Groote, Claudio Ronco, Alexander Zarbock
IntroductionAcute kidney injury (AKI) is a common complication after cardiac surgery (CS) and is associated with adverse short-term and long-term outcomes. Alpha-1-microglobulin (A1M) is a circulating glycoprotein with antioxidant, heme binding and m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1fa067b440256bd40c13918890a33d1
https://mediatum.ub.tum.de/1707613
https://mediatum.ub.tum.de/1707613
Autor:
Tobias E Larsson, Hartmut Onkels, Sven Hoefman, Nelleke Snelder, Kirsten R. Bergmann, Alberto Garcia-Hernandez
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics
ASP8232 is a novel inhibitor of vascular adhesion protein-1 that was under evaluation for reducing residual albuminuria in patients with diabetic kidney disease. To characterize the pharmacokinetics (PK) of ASP8232 and its effect on vascular adhesion
Autor:
Nelleke Snelder, Tobias E Larsson, Sven Hoefman, Kirsten R. Bergmann, Alberto Garcia-Hernandez, Martijn van Noort, Hartmut Onkels
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics
The vascular adhesion protein-1 (VAP-1) inhibitor ASP8232 reduces albuminuria in patients with type 2 diabetes and chronic kidney disease. A mechanism-based model was developed to quantify the effects of ASP8232 on renal markers from a placebo-contro
Autor:
Tammi Arbel Rubinstein, Inbal Reuveni, Arkadi Hesin, Anat Klein-Goldberg, Hannes Olauson, Tobias E. Larsson, Carmela R. Abraham, Ella Zeldich, Assumpció Bosch, Miguel Chillón, Kenneth Samuel Hollander, Ayelet Shabtay-Orbach, Gilad W. Vainer, Ido Wolf, Tami Rubinek
Publikováno v:
Cancers, Vol 13, Iss 6297, p 6297 (2021)
Cancers; Volume 13; Issue 24; Pages: 6297
Cancers
Scientia
Cancers; Volume 13; Issue 24; Pages: 6297
Cancers
Scientia
Simple Summary We aimed to study the role of the anti-aging protein klotho and its secreted isoform, sKL, in pancreatic cancer. Three in vivo models, including a novel genetic mouse model and bioinformatics analyses, indicated klotho as a tumor suppr
Autor:
Ozgur Asar, Peter J. Diggle, Tobias E. Larsson, Rachel J. Middleton, Sara T. Ibrahim, Anders Larsson, James Ritchie, Rajkumar Chinnadurai, Helen Alderson, Philip A. Kalra
Publikováno v:
BMC Nephrology, Vol 22, Iss 1, Pp 1-7 (2021)
BMC Nephrology
BMC Nephrology
Background Fibroblast growth factor23 (FGF23) is elevated in CKD and has been associated with outcomes such as death, cardiovascular (CV) events and progression to Renal Replacement therapy (RRT). The majority of studies have been unable to account f
Autor:
Jun-ichi Hanai, Marie Courbebaisse, Hannes Olauson, Beate Lanske, Rui Ye, Michael J. Densmore, Noriko Ide, Tobias E. Larsson
Publikováno v:
American Journal of Physiology-Renal Physiology. 315:F1261-F1270
Phosphate homeostasis is primarily maintained in the renal proximal tubules, where the expression of sodium/phosphate cotransporters (Npt2a and Npt2c) is modified by the endocrine actions of both fibroblast growth factor 23 (FGF23) and parathyroid ho